# Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

> **NCT00644189** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 50 (actual)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma
- Low Grade B-cell Lymphoma, Not Otherwise Specified
- Diffuse Large B-cell Lymphoma
- Peripheral T-cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Large-cell Lymphoma

## Interventions

- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00644189
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2013-12
- **Final completion:** 2021-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644189, "Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00644189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*